Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Barriers and Facilitators of Colorectal Cancer Screening in a Federally Qualified Health Center (FQHC).

Ylitalo KR, Camp BG, Umstattd Meyer MR, Barron LA, Benavidez G, Hess B, Laschober R, Griggs JO.

J Am Board Fam Med. 2019 Mar-Apr;32(2):180-190. doi: 10.3122/jabfm.2019.02.180205.

2.

Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.

Ludwig H, Cortelezzi A, Scheithauer W, Van Camp BG, Kuzmits R, Fillet G, Peetermans M, Polli E, Flener R.

Eur J Cancer Clin Oncol. 1986 Sep;22(9):1111-6.

3.

Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.

Ludwig H, Cortelezzi A, Van Camp BG, Polli E, Scheithauer W, Kuzmits R, Linkesch W, Gisslinger H, Sinzinger H, Fritz E, et al.

Oncology. 1985;42 Suppl 1:19-25.

PMID:
4080297
4.

[Interferon in the treatment of multiple myeloma].

Kuzmits R, Ludwig H, Cortelezzi A, Van Camp BG, Polli E, Flener R, Scheithauer W.

Acta Med Austriaca. 1985;12(5):135-8. German.

PMID:
3914174
5.

The cellular basis of double paraproteinemia in man.

van Camp BG, Shuit HR, Hijmans W, Radl J.

Clin Immunol Immunopathol. 1978 Jan;9(1):111-9. No abstract available.

PMID:
411620
6.

HLA antigens and homogeneous immunoglobulins.

Van Camp BG, Cole J, Peetermans ME.

Clin Immunol Immunopathol. 1977 May;7(3):315-8. No abstract available.

PMID:
406112

Supplemental Content

Support Center